EMPAGLIFLOZIN USE AND THE RISK OF NEPHROLITHIASIS IN PATIENTS WITH TYPE 2 DIABETES

被引：0

作者：

Tang, Francesca ^{[1
]}

Paik, Julie ^{[2
,3
]}

Tesfaye, Helen ^{[2
,3
]}

Zakoul, Heidi ^{[2
,3
]}

Schmedt, Niklas ^{[5
]}

Koeneman, Lisette ^{[6
]}

Seman, Leo ^{[7
]}

Curhan, Gary C. ^{[2
,3
]}

Wexler, Deborah J. ^{[3
,4
]}

Patorno, Elisabetta ^{[2
,3
]}

机构：

[1] Boehringer Ingelheim Pty Ltd, N Ryde, Australia

[2] Brigham & Womens Hosp, Boston, MA USA

[3] Harvard Med Sch, Boston, MA USA

[4] Massachusetts Gen Hosp, Boston, MA USA

[5] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[6] Lilly Deutschland GmbH, Bad Homburg, Germany

[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA

来源：

NEPHROLOGY | 2023年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：29 / 29

页数：1

共 50 条

[21] Empagliflozin and cardiovascular endpoints in patients with type 2 diabetes mellitus
Guthoff M.
Der Nephrologe, 2016, 11 (3): : 217 - 218
[22] Type 2 diabetes increases the risk of nephrolithiasis irrespective of overweight and age
Daudon, M.
Letavernier, E.
Haymann, J. P.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2013, 43 : 78 - 78
[23] Analysis of Risk Factors for Uric Acid Nephrolithiasis in Type 2 Diabetes
Kumar, K. V. S. Hari
Modi, K. D.
SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2011, 22 (03) : 482 - 487
[24] Empagliflozin: A Review in Type 2 Diabetes
Frampton, James E.
DRUGS, 2018, 78 (10) : 1037 - 1048
[25] Empagliflozin for the treatment of type 2 diabetes
Jahagirdar, Vidhya
Barnett, Anthony H.
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (16) : 2429 - 2441
[26] Empagliflozin: A Review in Type 2 Diabetes
James E. Frampton
Drugs, 2018, 78 : 1037 - 1048
[27] Empagliflozin for the treatment of Type 2 diabetes
Komala, Muralikrishna Gangadharan
Mather, Amanda
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (03) : 271 - 279
[28] Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study
Tesfaye, Helen
Paik, Julie M.
Zakoul, Heidi
Schmedt, Niklas
Wexler, Deborah J.
Patorno, Elisabetta
DIABETES OBESITY & METABOLISM, 2025,
[29] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT HIGH CARDIOVASCULAR RISK IN POLAND
Pawlik, D.
Wojcik, R.
Zawodnik, A.
Kaczor, M. P.
VALUE IN HEALTH, 2017, 20 (09) : A478 - A478
[30] Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Anderson, John E.
Wright, Eugene E., Jr.
Shaefer, Charles F., Jr.
DIABETES THERAPY, 2017, 8 (01) : 33 - 53

← 1 2 3 4 5 →